Document Detail

HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
MedLine Citation:
PMID:  20679181     Owner:  NLM     Status:  MEDLINE    
Reactive oxygen species and proinflammatory cytokines contribute to cardiovascular diseases. Inhibition of downstream transcription factors and gene modifiers of these components are key mediators of hypertensive response. Histone acetylases/deacetylases can modulate the gene expression of these hypertrophic and hypertensive components. Therefore, we hypothesized that long-term inhibition of histone deacetylase with valproic acid might attenuate hypertrophic and hypertensive responses by modulating reactive oxygen species and proinflammatory cytokines in SHR rats. Seven-week-old SHR and WKY rats were used in this study. Following baseline blood pressure measurement, rats were administered valproic acid in drinking water (0.71% wt/vol) or vehicle, with pressure measured weekly thereafter. Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension. Following 20 weeks of treatment, heart function was measured using echocardiography, rats were euthanized, and heart tissue was collected for measurement of total reactive oxygen species, as well as proinflammatory cytokine, cardiac hypertrophic, and oxidative stress gene and protein expressions. Blood pressure, proinflammatory cytokines, hypertrophic markers, and reactive oxygen species were increased in SHR versus WKY rats. These changes were decreased in valproic acid-treated SHR rats, whereas hydralazine treatment only reduced blood pressure. These data indicate that long-term histone deacetylase inhibition, independent of the blood pressure response, reduces hypertrophic, proinflammatory, and hypertensive responses by decreasing reactive oxygen species and angiotensin II type1 receptor expression in the heart, demonstrating the importance of uncontrolled histone deacetylase activity in hypertension.
Jeffrey P Cardinale; Srinivas Sriramula; Romain Pariaut; Anuradha Guggilam; Nithya Mariappan; Carrie M Elks; Joseph Francis
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-08-02
Journal Detail:
Title:  Hypertension     Volume:  56     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-19     Completed Date:  2010-09-13     Revised Date:  2014-06-11    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  437-44     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology
Blood Pressure / drug effects*
Cardiomegaly / drug therapy*,  metabolism,  physiopathology
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylases / metabolism*
Hydralazine / pharmacology
Hypertension / drug therapy*,  metabolism,  physiopathology
Inflammation / drug therapy*,  metabolism,  physiopathology
Rats, Inbred SHR
Rats, Inbred WKY
Valproic Acid / pharmacology*,  therapeutic use
Grant Support
Reg. No./Substance:
0/Antihypertensive Agents; 0/Histone Deacetylase Inhibitors; 26NAK24LS8/Hydralazine; 614OI1Z5WI/Valproic Acid; EC Deacetylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Upregulation of Ecto-5'-Nucleotidase by Rosuvastatin Increases the Vasodilator Response to Ischemia.
Next Document:  Postmenopausal hypertension: role of the Renin-Angiotensin system.